Despite government rhetoric hailing the life sciences sector as one of the UK’s “crown jewels,” industry leaders are warning that its luster is fading fast. A growing number of pharmaceutical companies are pulling back on investment, citing an unfavorable and expensive operating environment, turning the UK into a “terrible place to sell medicines,” according to a Sanofi executive.
The evidence of this decline is mounting. MSD’s recent cancellation of its £1bn London research center sent shockwaves through the industry. This was followed by news that Eli Lilly has paused its plans for a London incubator lab. Sanofi, a major French drugmaker, has also significantly scaled back its UK presence, cutting clinical trials by half and shelving plans for expansion.
At the heart of the dispute are financial policies that the industry deems unsustainable. The UK’s spending on medicines as a percentage of healthcare costs is significantly lower than in the US, Germany, Spain, and Italy. The pricing guidelines used by NICE are over two decades old, and a punitive “clawback” rate forces companies to return a large slice of their revenues to the NHS.
Experts and industry bodies are now united in their call for urgent government intervention. They demand a coherent strategy to align UK spending and commercial terms with international competitors. The consensus is clear: without swift and decisive action, the UK’s reputation as a world leader in medical research and development is in serious jeopardy.